CN114377110A - Application of compound RKC-B1 in inhibition of neuroinflammation - Google Patents

Application of compound RKC-B1 in inhibition of neuroinflammation Download PDF

Info

Publication number
CN114377110A
CN114377110A CN202011130883.XA CN202011130883A CN114377110A CN 114377110 A CN114377110 A CN 114377110A CN 202011130883 A CN202011130883 A CN 202011130883A CN 114377110 A CN114377110 A CN 114377110A
Authority
CN
China
Prior art keywords
rkc
lps
group
neuroinflammation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011130883.XA
Other languages
Chinese (zh)
Inventor
王月华
杜冠华
刘漫
杨滢霖
张姗姗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CN202011130883.XA priority Critical patent/CN114377110A/en
Publication of CN114377110A publication Critical patent/CN114377110A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses application of a compound RKC-B1 shown in a formula (I) in inhibiting neuroinflammation, and belongs to the technical field of medicines. Pharmacological experiments prove that: RKC-B1 can remarkably inhibit IL (interleukin) of mouse brain cortex, hippocampus and striatum tissue inflammatory factor induced by LPS (lipopolysaccharide)Release of-1 beta (IL-1 beta), interleukin-6 (IL-6), monocyte chemotactic factor MCP-1, intercellular adhesion molecule-1 (ICAM-1), have significant neuroinflammatory activity. Therefore, the compound can be used for preparing medicines for preventing and/or treating neuroinflammation and related central nervous system diseases such as traumatic brain injury, cerebral apoplexy, Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington's chorea and the like, and has higher clinical application value and development prospect.

Description

Application of compound RKC-B1 in inhibition of neuroinflammation
Technical Field
The invention belongs to the technical field of medicines, and relates to application of RKC-B1 in medicines for inhibiting neuroinflammation and related central nervous system diseases such as traumatic brain injury, cerebral apoplexy, Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington's chorea and the like.
Background
Neuroinflammatory response is a complex cascade of progressive development, mainly manifested by activation and proliferation of glial cells, infiltration of peripheral inflammatory cells, and expression of associated inflammatory cytokines. Neuroinflammatory responses play a key role in the pathogenesis of central nervous system diseases such as traumatic brain injury, cerebral stroke, alzheimer's disease, parkinson's disease, huntington's chorea, and the like. Microglia are immune cells of the central nervous system, and brain injury induces microglia activation and release of inflammatory factors and adhesion molecules, such as interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), single cell chemokine (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and the like. These factors interact and modulate each other, leading to neuronal damage, degeneration and even death, and controlling neuroinflammation is a breakthrough point in delaying or treating these neurological diseases.
LPS is a major component of the cell wall of gram-negative bacteria and is a potent inducer of inflammatory responses. Animal experiment research shows that mice can induce the activation of astrocytes and microglia by LPS (lipopolysaccharide) after intraperitoneal injection, and the expression of inflammatory cytokines in brains is promoted. LPS-induced inflammatory reaction becomes a classical reagent for preparing a neuroinflammation animal model, and is widely used for screening, evaluating and mechanism research of medicaments with anti-inflammatory activity.
The compound derived from marine microorganisms has biological diversity, and the metabolic products have complex and changeable structures, which contain infinite structural diversity. Obtaining compounds capable of inhibiting neuroinflammation from marine natural products is an important approach for drug development in this field. RKC-B1 is derived from Micromonospora maritima FIM02-523, and B1 monocomponent fermentation production is realized through high-yield strain breeding and fermentation optimization. Few reports on the pharmacological activity of RKC-B1 exist at present, and no report on RKC-B1 for inhibiting neuroinflammation and related nervous system diseases exists.
Disclosure of Invention
The invention uses an LPS (lipopolysaccharide) intraperitoneal injection induced neuroinflammation mouse model to evaluate the anti-neuritis activity of RKC-B1. The structural formula of the compound RKC-B1 is shown as the formula I:
Figure BDA0002735130250000021
one of the technical problems to be solved by the invention is as follows: provides the application of RKC-B1 shown in the formula (I) in medicines and other products related to the aspect of inhibiting neuroinflammation.
The second technical problem to be solved by the invention is as follows: RKC-B1 shown in (I) is provided for preventing and/or treating central nervous system diseases such as traumatic brain injury, cerebral apoplexy, Alzheimer's disease, Parkinson's disease, Huntington's chorea and the like caused by neuroinflammation.
The compound RKC-B1 can obviously reduce the increase of the LPS induced factors IL-1 beta, IL-6, MCP-1 and ICAM-1 related to the inflammatory response of the cerebral cortex, hippocampus and striatum tissues of a mouse, and shows that RKC-B1 has obvious activity of resisting neuritis.
In addition, the invention also discloses a medicament and other products which are prepared by using RKC-B1 as an active ingredient and used for preventing and/or treating and inhibiting neuroinflammation and related central nervous system diseases such as traumatic brain injury, cerebral apoplexy, Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington's chorea and the like.
The invention also relates to pharmaceutical compositions of the compounds of the invention and conventional pharmaceutical excipients or adjuvants.
Pharmaceutical compositions of the compounds of the invention may be prepared according to methods well known in the art. For this purpose, the compounds of the invention can, if desired, be combined with one or more solid or liquid pharmaceutical excipients and/or adjuvants and brought into a suitable administration form or dosage form for use as human or veterinary medicine.
The compounds of the present invention or pharmaceutical compositions containing them may be administered in unit dosage form by enteral or parenteral routes, such as oral, intramuscular, subcutaneous, nasal, oromucosal, dermal, peritoneal or rectal administration.
The route of administration of the compounds of the invention or the pharmaceutical compositions containing them may be by injection. The injection includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, acupoint injection, etc.
The administration dosage form can be liquid dosage form or solid dosage form. For example, the liquid dosage form can be true solution, colloid, microparticle, emulsion, or suspension. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, suppository, lyophilized powder for injection, etc.
The compound can be prepared into common preparations, sustained release preparations, controlled release preparations, targeting preparations and various microparticle drug delivery systems.
The beneficial technical effects are as follows: the compound has outstanding pharmacological activity and is suitable for various diseases of the nervous system.
Drawings
FIG. 1 effect of 1 RKC-B1 on LPS-induced IL-1 β levels in mouse brain cortex tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 2 effect of 2 RKC-B1 on LPS-induced IL-6 levels in mouse brain cortex tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.05, P <0.01 compared to LPS model group.
FIG. 3 effect of 3 RKC-B1 on LPS-induced MCP-1 levels in mouse brain cortex tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 4 effect of 4 RKC-B1 on LPS-induced ICAM-1 levels in mouse brain cortex tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 5 effect of 5 RKC-B1 on LPS-induced IL-1 β levels in mouse hippocampal brain tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 6 RKC-B1 Effect on LPS-induced IL-6 levels in mouse hippocampal brain tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.05, P <0.01 compared to LPS model group.
FIG. 7 effect of 7 RKC-B1 on LPS-induced MCP-1 levels in hippocampal tissue of mice. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 8 effect of 8 RKC-B1 on LPS-induced IL-1 β levels in mouse striatal brain tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 9 effect of 9 RKC-B1 on LPS-induced IL-6 levels in mouse brain striatum tissues. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 10 effect of 10 RKC-B1 on LPS-induced MCP-1 levels in mouse striatal brain tissue. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
FIG. 11 effect of 11 RKC-B1 on LPS-induced ICAM-1 levels in mouse brain striatum tissues. Data are expressed as mean ± SD. compared to control, # # P < 0.01; p <0.01 compared to LPS model group.
Detailed Description
RKC-B1 has effects in inducing neuroinflammation of mouse cerebral cortex, hippocampus and striatum tissue by LPS
1. Experimental methods
1.1 animal grouping and administration
Reagent LPS (Sigma); IL-1. beta., IL-6, MCP-1, ICAM-1 detection ELISA kit (Girtex SpA. Biotech Co., Ltd.).
The experimental animal adult male BALB/c mouse has a weight of 20-22 g, and has an animal quality qualification number of SYXK 2016-. Feeding under normal conditions, wherein the temperature is 25 +/-1 ℃, the relative humidity is 55-65%, and the water is freely fed after 12h of illumination period.
Animal grouping and dosing animals were randomly grouped after 3 days of acclimation: solvent control group (Vehicle), LPS model group (LPS), RKC-B15 mg/kg administration group (LPS + RKC-5mg/kg), RKC-B110 mg/kg administration group (LPS + RKC-10 mg/kg). The solvent control group and the LPS model group are injected into the abdominal cavity with equal volume of solvent (containing 0.1% Tween80 normal saline) for 7 days continuously; RKC-B15, 10mg/kg administration group, intraperitoneal injection and administration for 7 days. After the last administration, LPS 5mg/kg is injected into the abdominal cavity of LPS model group, RKC-B15 and 10mg/kg group; the solvent control group was injected with an equal volume of saline intraperitoneally. Materials were taken 6h after LPS injection. 8 tissues of cortex, hippocampus, and striatum were isolated per group and cryopreserved in a-80 ℃ freezer for later ELISA testing.
1.2 ELISA detection
Tissues of a specific part of the mouse were weighed and 1mL of pre-cooled physiological saline was added to 100mg of the tissue. Grinding with hand-held homogenizer on ice to obtain homogenate, centrifuging at 4500r/min at 4 deg.C for 15min, and collecting supernatant. The BCA method is used for measuring the protein content, and the ELISA kit is used for detecting the contents of IL-1 beta, IL-6, MCP-1 and ICAM-1. The method is carried out according to the specification, and the brief operation steps are as follows: adding a sample to be detected or standard substance solutions with different concentration gradients into a 96-hole ELISA plate, adding a biotinylated antibody working solution, incubating for 120min at room temperature, fully washing, removing the sample and the biotinylated antibody working solution, adding an HRP (horse radish peroxidase) labeled secondary antibody except blank holes, and incubating for 60min at room temperature; discarding the secondary antibody solution, fully washing, adding a chromogenic substrate, and incubating for 15min at room temperature in a dark place; detecting absorbance value at 450nm within 10min after adding stop solution, and calculating the content of inflammatory factor by drawing a standard curve.
The experimental results are as follows:
compared with a normal control group, the levels of inflammatory response related factors IL-1 beta, IL-6, MCP-1 and ICAM-1 in the cortex tissues of the mice in the LPS model group are obviously increased; RKC-B15 and 10mg kg-1The administration groups all significantly reduced the increase of inflammatory response-associated factors IL-1 beta (Table 1, FIG. 1), IL-6 (Table 2, FIG. 2), MCP-1 (Table 3, FIG. 3) and ICAM-1 (Table 4, FIG. 4) in the mouse cortex tissue induced by LPS.
TABLE 1 Effect of 1 RKC-B1 on LPS-induced IL-1 β levels in mouse brain cortex tissue
Group of IL-1 beta (pg/mg protein)
Normal control group 31.68±6.30
LPS model group 182.50±67.82##
LPS + RKC-B15 mg/kg group 68.99±29.81**
LPS + RKC-B110 mg/kg group 58.02±29.85**
TABLE 2 effects of 2 RKC-B1 on LPS-induced IL-6 levels in mouse brain cortex tissue
Group of IL-6(pg/mg protein)
Normal control group 2.30±0.53
LPS model group 22.46±11.83##
LPS + RKC-B15 mg/kg group 4.81±1.91**
LPS + RKC-B110 mg/kg group 12.26±8.62*
TABLE 3 effects of 3 RKC-B1 on LPS-induced MCP-1 levels in mouse brain cortex tissue
Group of MCP-1(pg/mg protein)
Normal control group 3.66±1.35
LPS model group 1607.18±741.02##
LPS + RKC-B15 mg/kg group 393.32±216.90**
LPS + RKC-B110 mg/kg group 404.56±236.50**
TABLE 4 effects of 4 RKC-B1 on LPS-induced ICAM-1 levels in mouse brain cortex tissue
Group of ICAM-1(pg/mg protein)
Normal control group 59.76±8.23
LPS model group 267.89±77.82##
LPS + RKC-B15 mg/kg group 161.76±67.94**
LPS + RKC-B110 mg/kg group 159.21±56.24**
Compared with a normal control group, the levels of inflammatory response related factors IL-1 beta, IL-6, MCP-1 and ICAM-1 in hippocampal tissues of mice in an LPS model group are obviously increased; RKC-B15 and 10mg kg-1The administration group can remarkably reduce the increase of inflammatory response related factors IL-1 beta (table 5, figure 5), IL-6 (table 6, figure 6) and MCP-1 (table 7, figure 7) in mouse hippocampal tissues induced by LPS.
TABLE 5 Effect of 5 RKC-B1 on LPS-induced IL-1 β levels in mouse hippocampal brain tissue
Group of IL-1 beta (pg/mg protein)
Normal control group 24.77±6.56
LPS model group 126.35±31.08##
LPS + RKC-B15 mg/kg group 77.30±31.89**
LPS + RKC-B110 mg/kg group 57.73±30.21**
TABLE 6 effects of 6 RKC-B1 on LPS-induced IL-6 levels in mouse hippocampal brain tissue
Figure BDA0002735130250000061
Figure BDA0002735130250000071
TABLE 7 Effect of 7 RKC-B1 on LPS-induced MCP-1 levels in hippocampal brain tissue of mice
Group of MCP-1(pg/mg protein)
Normal control group 22.42±5.39
LPS model group 697.08±386.51##
LPS + RKC-B15 mg/kg group 265.51±179.16**
LPS + RKC-B110 mg/kg group 209.84±128.55**
Compared with a normal control group, the levels of proinflammatory factors IL-1 beta, IL-6, MCP-1 and ICAM-1 in striatum tissues of mice in an LPS model group are obviously increased; RKC-B15 and 10mg kg-1The administration group can remarkably reduce the increase of inflammation-related factors IL-1 beta (Table 8, figure 8), IL-6 (Table 9, figure 9), MCP-1 (Table 10, figure 10) and ICAM-1 (Table 11, figure 11) in striatal tissues of mice induced by LPS.
TABLE 8 Effect of 8 RKC-B1 on LPS-induced IL-1 β levels in mouse brain striatum tissues
Group of IL-1 beta (pg/mg protein)
Normal control group 36.30±7.37
LPS model group 109.16±27.42##
LPS + RKC-B15 mg/kg group 58.96±12.06**
LPS + RKC-B110 mg/kg group 64.60±16.72**
TABLE 9 Effect of 9 RKC-B1 on LPS-induced IL-6 levels in mouse brain striatum tissues
Group of IL-6(pg/mg protein)
Normal control group 4.40±0.69
LPS model group 23.35±5.00##
LPS + RKC-B15 mg/kg group 7.20±0.75**
LPS + RKC-B110 mg/kg group 9.05±2.35**
TABLE 10 effects of 10 RKC-B1 on LPS-induced MCP-1 levels in mouse brain striatum tissues
Group of MCP-1(pg/mg protein)
Normal control group 2.38±0.82
LPS model group 547.14±244.91##
LPS + RKC-B15 mg/kg group 196.41±86.39**
LPS + RKC-B110 mg/kg group 175.52±142.81**
TABLE 11 effects of 11 RKC-B1 on LPS-induced ICAM-1 levels in mouse brain striatum tissues
Group of ICAM-1(pg/mg protein)
Normal control group 139.55±11.21
LPS model group 326.92±40.64##
LPS + RKC-B15 mg/kg group 233.62±55.06**
LPS + RKC-B110 mg/kg group 221.37±44.43**
。

Claims (5)

1. The application of the compound RKC-B1 shown in the general formula (I) or pharmaceutically acceptable salt thereof in preparing medicines for inhibiting neuroinflammation,
Figure FDA0002735130240000011
2. the application of the compound RKC-B1 shown in the general formula (I) or pharmaceutically acceptable salts thereof in preparing medicaments for preventing and/or treating acute and chronic central nervous system diseases caused by neuroinflammation,
Figure FDA0002735130240000012
3. the use of claim 2, wherein the acute or chronic neurological disease caused by neuroinflammation comprises: traumatic brain injury, cerebral stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis or Huntington's chorea.
4. The application of a pharmaceutical composition in preparing medicines for inhibiting neuroinflammation is characterized in that the pharmaceutical composition comprises a compound RKC-B1 shown in a general formula (I) or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier,
Figure FDA0002735130240000021
5. the application of a pharmaceutical composition in preparing a medicament for preventing and/or treating acute and chronic central nervous system diseases caused by neuroinflammation is characterized in that the pharmaceutical composition comprises a compound RKC-B1 shown in a general formula (I) or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier,
Figure FDA0002735130240000022
CN202011130883.XA 2020-10-21 2020-10-21 Application of compound RKC-B1 in inhibition of neuroinflammation Pending CN114377110A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011130883.XA CN114377110A (en) 2020-10-21 2020-10-21 Application of compound RKC-B1 in inhibition of neuroinflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011130883.XA CN114377110A (en) 2020-10-21 2020-10-21 Application of compound RKC-B1 in inhibition of neuroinflammation

Publications (1)

Publication Number Publication Date
CN114377110A true CN114377110A (en) 2022-04-22

Family

ID=81192599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011130883.XA Pending CN114377110A (en) 2020-10-21 2020-10-21 Application of compound RKC-B1 in inhibition of neuroinflammation

Country Status (1)

Country Link
CN (1) CN114377110A (en)

Similar Documents

Publication Publication Date Title
US20210290578A1 (en) Mixture of fatty acids for use in the treatment of inflammatory pathologies
CN110960539A (en) Application of mulberroside A and derivatives thereof in preparation of medicine for protecting intestinal barrier
US9636321B2 (en) Compositions and methods for treating psoriasis
CN104288168B (en) Purposes of the cryptogenin in the medicine for preparing the disease for being used for treating and/or prevent microglia to mediate
CN114377110A (en) Application of compound RKC-B1 in inhibition of neuroinflammation
CN110882264A (en) Pharmaceutical composition of gastrodin and mannuronic acid oligosaccharide and application thereof
CN114504588A (en) Application of aureomycin A in preparing medicine for inhibiting neuroinflammation
CN114504587A (en) Application of oleanolic acid compound in preparation of medicines for inhibiting neuroinflammation
CN109096190B (en) Sinomenine derivative, preparation method, application and pharmaceutical composition thereof
CN108542898A (en) Purposes of the cajanin and combinations thereof in preparing medicament for treatment of depression
CN114377028B (en) Application of compound aureomycin A in aspect of inhibiting kidney inflammation
US9629864B2 (en) Use of baicalin in preparation of drugs for treating acute hemolytic uremic syndrome
CN115475159A (en) Application of kaempferol in preparation of medicine for inhibiting cerebellar inflammatory reaction
CN112603920A (en) Application of traditional Chinese medicine toosendanin in preparation of products for preventing and treating glioma of nervous system
CN115804785A (en) Application of myricitrin in preparing medicine for inhibiting cerebellar inflammatory reaction
CN113827591B (en) Application of biotin in preparation of medicines for treating sepsis
CN113855670B (en) Application of A205804 in preparation of medicines for treating sepsis
CN110538232A (en) Anti-depression compound preparation and preparation method thereof
EP1666046A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
CN112274518B (en) Application of triptolide derivative in preparation of drugs for preventing and/or treating septicemia
WO2014029285A1 (en) Use of cordycepin in manufacture of medicaments for anti-depression
CN110833555B (en) Use of pyrazolopyrimidine derivatives for the treatment of ulcerative colitis
CN114099493B (en) Active compound for inhibiting insulin resistance and application thereof
CN117137897B (en) Application of sofalcone in preparation of medicine for preventing/treating psoriasis
CN108245510B (en) Composition of cannabidiol and acryloyl urea antiepileptic drugs and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination